A Three Month Prospective Open Label Study Of Therapy With Fragmin(Registered) (Dalteparin Sodium Injection) In Children With Venous Thromboembolism With Or Without Malignancies
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2017
At a glance
- Drugs Dalteparin sodium (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd; Pfizer
- 01 Nov 2016 Planned End Date changed from 1 May 2018 to 1 Apr 2018.
- 01 Nov 2016 Planned primary completion date changed from 1 May 2018 to 1 Apr 2018.
- 03 Oct 2016 Planned End Date changed from 1 Apr 2018 to 1 May 2018.